# Viking Therapeutics, Inc. (VKTX) Stock Analysis: Unpacking the 175% Potential Upside

- Link: https://www.directorstalkinterviews.com/viking-therapeutics-inc-vktx-stock-analysis-unpacking-the-175-potential-upside/4121243779
- Published: 2026-03-10T11:20:06+00:00
- Author: Madison Wilson

Investors are taking a keen interest in Viking Therapeutics, Inc. (NASDAQ: VKTX),
a clinical-stage biopharmaceutical company, as it continues to make waves in the
biotechnology sector. With a market capitalization of $3.88 billion, the company
has captured attention with its groundbreaking research and development efforts 
targeting metabolic and endocrine disorders. The most intriguing aspect for potential
investors is the staggering 175.88% potential upside, based on the average analyst
target price of $92.72 compared to its current price of $33.61.

Viking Therapeutics is currently developing several promising drug candidates. Its
flagship therapy, VK2809, is advancing through Phase IIb clinical trials targeting
non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
The company also has other notable candidates such as VK5211 for hip fracture recovery,
VK0612 for metabolic disorders, and VK2735, which is in early-stage trials.

Despite the promising pipeline, the financial metrics present a mixed picture. The
company is yet to generate revenue, and its earnings per share (EPS) stands at -
3.19, reflective of its developmental stage. The forward P/E ratio of -7.35 and 
a concerning return on equity of -47.34% signal that profitability is not on the
immediate horizon. Furthermore, the company’s free cash flow is negative, indicating
substantial cash burn, typical for biotech firms in the research and development
phase.

From a technical standpoint, Viking’s stock is trading above both its 50-day and
200-day moving averages, positioned at $32.04 and $31.65 respectively. This suggests
a positive trend, albeit with a Relative Strength Index (RSI) of 41.83, which indicates
that the stock is neither overbought nor oversold, offering a neutral stance on 
its momentum.

The analyst ratings are overwhelmingly optimistic, with 17 buy recommendations and
only a single hold rating, underscoring the high expectations for Viking’s growth
potential. The significant target price range of $35.00 to $125.00 reflects the 
anticipated variability in outcomes contingent on the success of their clinical 
trials.

While Viking Therapeutics does not offer a dividend, indicating a focus on reinvestment
into its pipeline, the zero dividend payout ratio is typical for a biotechnology
firm at this stage, as it prioritizes funding its ambitious R&D agenda.

For investors with a high-risk tolerance and a long-term horizon, Viking Therapeutics
presents an intriguing opportunity, bolstered by its innovative pipeline and strong
analyst support. However, the inherent risks associated with clinical trials and
the time required to transition from a clinical-stage to a revenue-generating company
should be carefully weighed. As Viking continues its quest toward medical breakthroughs,
its journey will undoubtedly be one to watch.

Share on:
